ConductScience.org, home

Paper3667166

A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies.

Yamada K and 9 others. Invest New Drugs, 1987. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies. Papers, record 3667166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3667166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies.
PubMed
Journal
Invest New Drugs
PubMed
Year
1987
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.15
iCite
Revised in PubMed
2026-10-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yamada KK
2Shirakawa SS
3Ohno RR
4Yamada HH
5Hirota YY
6Ohara KK
7Yamagata KK
8Kobayashi MM
9Hirano MM
10Ikeda YY

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DoxorubicinMajor topic
LeukemiaMajor topic
LymphomaMajor topic
Acute Disease
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Child
Drug Evaluation
Female
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

References14

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14353012A clinicopathologic analysis of adriamycin cardiotoxicity.Cancer1973https://conductscience.org/library/papers/4353012PubMed
2528373Tetrahydropyranyl derivatives of daunomycin and adriamycin.J Antibiot (Tokyo)1979https://conductscience.org/library/papers/528373PubMed
36882000[Preliminary phase II clinical study of 4'-O-tetrahydropyranyl doxorubicin (THP-ADM)].Gan To Kagaku Ryoho1983https://conductscience.org/library/papers/6882000PubMed
46588924[Effects of single administration of tetrahydropyranyladriamycin (THP) in lymphoid malignancy].Gan To Kagaku Ryoho1984https://conductscience.org/library/papers/6588924PubMed
55365804Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius.Biotechnol Bioeng1969https://conductscience.org/library/papers/5365804PubMed
6528374Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.J Antibiot (Tokyo)1979https://conductscience.org/library/papers/528374PubMed
76501106The absolute structures of THP-adriamycins.J Antibiot (Tokyo)1984https://conductscience.org/library/papers/6501106PubMed
86696455[Phase II study of 4'-O-tetrahydropyranyladriamycin(THP-ADM)].Gan To Kagaku Ryoho1984https://conductscience.org/library/papers/6696455PubMed
94512953Daunorubicin in the therapy of acute granulocytic leukemia.Cancer Res1973https://conductscience.org/library/papers/4512953PubMed
106833151Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin.J Antibiot (Tokyo)1983https://conductscience.org/library/papers/6833151PubMed
116580842[Phase II study of THP-adriamycin in acute leukemia].Gan To Kagaku Ryoho1983https://conductscience.org/library/papers/6580842PubMed
126202243[Acute cardiotoxicity of anthracyclines--analysis by using Holter ECG].Gan To Kagaku Ryoho1984https://conductscience.org/library/papers/6202243PubMed
136678865Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin.Invest New Drugs1983https://conductscience.org/library/papers/6678865PubMed
1470600204'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.Cancer Res1982https://conductscience.org/library/papers/7060020PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn Papers
40451863The outcome of patients with peripheral T cell lymphoma treated with doxorubicin-based (CHOP) and pirarubicin-based regimen (THP-COP) regimen: a single institution experience.J Clin Exp Hematop2025https://conductscience.org/library/papers/40451863

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3667166

GET https://conductscience.org/api/papers/v1/3667166/authors